Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

Company Overview

Adial Pharmaceuticals, Inc., incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence. This extended-release formulation aims to improve compliance and reduce relapse rates by maintaining therapeutic drug levels without the need for daily dosing. In addition to AD04, Adial is evaluating next-generation implant platforms and potential adjunctive therapies for substance use disorders, seeking to broaden its pipeline through strategic collaborations and in-house research efforts.

Adial conducts clinical research primarily in North America, with previous trials extending to select international sites to gather comprehensive safety and efficacy data supporting future regulatory filings. The company operates through partnerships with academic institutions, contract research organizations and specialized clinical investigators to advance its development programs. Led by an executive team with extensive experience in pharmaceutical development, regulatory affairs and commercialization, Adial Pharmaceuticals continues to focus on addressing global challenges in addiction medicine and preparing for regulatory submissions that could pave the way for market entry.

Key Stats

• Today's Range: $1.58 to $1.64
• 50-Day Range: $1.54 to $2.53
• 52-Week Range: $1.51 to $18.90
• Volume: 58,737 shs
• Average Volume: 99,211 shs
• Market Capitalization: $2.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.75
• Consensus Rating: Hold

Adial Pharmaceuticals Stock Analysis - MarketRank™

Adial Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Adial Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Adial Pharmaceuticals has a consensus price target of $22.75, representing about 1,321.9% upside from its current price of $1.60.

Amount of Analyst Coverage

Adial Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Adial Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adial Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adial Pharmaceuticals has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.50% of the float of Adial Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.55, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adial Pharmaceuticals has recently decreased by 49.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adial Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Adial Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Adial Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for ADIL on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.86% of the stock of Adial Pharmaceuticals is held by insiders.

Percentage Held by Institutions

16.41% of the stock of Adial Pharmaceuticals is held by institutions.

ADIL Stock Analysis - Frequently Asked Questions

How have ADIL shares performed this year?

Adial Pharmaceuticals' stock was trading at $5.50 on January 1st, 2026. Since then, ADIL stock has decreased by 70.9% and is now trading at $1.60.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) issued its quarterly earnings data on Thursday, November, 13th. The company reported ($2.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.25) by $0.25.

When did Adial Pharmaceuticals' stock split?

Adial Pharmaceuticals's stock reverse split on Friday, February 6th 2026.The 1-25 reverse split was announced on Tuesday, February 3rd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Adial Pharmaceuticals IPO?

Adial Pharmaceuticals (ADIL) raised $15 million in an initial public offering on Friday, July 27th 2018. The company issued 1,464,000 shares at $9.00-$11.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), Arista Networks (ANET) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 11/13/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADIL
• CIK: 1513525
• Web: www.adialpharma.com
• Phone: (434) 422-9800
• Fax: N/A
• Employees: 20
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Adial Pharmaceuticals: $22.75
• High Price Target: $37.50
• Low Price Target: $8.00
• Potential Upside/Downside: +1,321.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($18.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -182.34%
• Return on Assets: -141.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.42
• Quick Ratio: 4.42

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.75 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 1,430,000
• Free Float: 1,401,000
• Market Cap: $2.29 million
• Optionable: No Data
• Beta: 1.27